Insights

At Inbeeo, Market Access truly is our passion and we love to share our thoughts on the latest developments in the field through our blog and also in publications. Should you have a topic that you would value our thoughts on then please do get in touch – we would love to hear from you.

The Inbeeo Market Access Consulting Team
Market Access Challenges for ATMPs

How Payers in the US & Europe are adapting to the ATMP revolution

So what are ATMPs exactly and why all the fuss about these therapies and the impact they are having within the market? Inbeeo hosted a free to attend webinar looking into this topic focusing on some specific country challenges within the US and EU, with 60+ attendees contributing to the discussion during the Q&A.
ASMR Ratings Given to New Products in France since 2008

In France, the value equation may change (a little)

France's healthcare industry strategic council CSIS met an agreement with the French Government to strengthen France’s appeal for HealthCare industries. Inbeeo dives in to investigate the impact on market access and pricing.
The Six Drugs that on Average Cost Patients over $10,000 a Year

Six Drugs that Cost a Medicare Part D Beneficiary more than $10,000 a Year

No one will argue that Medicare Part D met a genuine need at its inception in the mid-2000s - offering Medicare beneficiaries an affordable voluntary health insurance plan that would cover their outpatient prescription needs. Fast forward 10 years. Has Part D met its objective? In terms of the availability of a wide range of plans at an affordable premium in all parts of the nation, yes, definitely. In terms of actual payments made to beneficiaries, this is a question mark.
All articles loaded
No more articles to load